The Hindu·3 min read·medium
U.S. FDA approves first mRNA flu shot from Moderna
R
Reuters
✦AI Summary
The U.S. FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This marks the first time mRNA technology has been authorized for a seasonal flu shot, though commercial impact is not expected until 2027.
The U.S. Food and Drug Administration has approved Moderna’s flu vaccine for people aged 50 and older, the company said on Wednesday (August 5, 2026), marking the first approval of a messenger RNA-based vaccine for seasonal flu.
healthsciencebusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in